BioCentury
ARTICLE | Clinical News

Ezutromid regulatory update

October 3, 2016 7:00 AM UTC

FDA granted rare pediatric disease designation to Summit’s ezutromid to treat Duchenne muscular dystrophy (DMD). The small molecule utrophin (UTRN) modulator is in Phase II testing (see BioCentury, J...